T-cell therapy for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma (stage IIIc or IV) that cannot be surgically removed or has spread to other parts of your body.
- You have already tried a PD-1 checkpoint inhibitor (like Keytruda or Opdivo) and your cancer continued to grow.
- You are between 18 and 75 years old and in fairly good health (able to do everyday activities).
- You have at least one melanoma tumor (bigger than a sugar cube) that can be surgically removed to make the special T-cells.
- Your heart and other organs (like kidneys, liver, and blood counts) must be working well enough to handle the treatment.
- You cannot have more than 2 small, stable brain metastases; any active or large brain spots must be treated first.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a personalized cell therapy using your own immune cells (TILs) grown in a lab. It is for people with advanced melanoma that did not respond to or stopped responding to prior immunotherapy.
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
This trial tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to other therapies. It involves taking immune cells from a tumor, growing them in a lab, and giving them back to fight the cancer.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
Hear when a new Melanoma Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.